Catalyst Pharmaceuticals Inc

CPRX

23.070USD

-0.250-1.07%

Close 03/24, 16:00（ET）Quotes delayed by 15 min

Catalyst Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

5 / 157

Overall Ranking

38 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Catalyst Pharmaceuticals Inc Highlights

StrengthsRisks

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 47.91% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 588.99M.

Undervalued

The company’s latest PE is 13.16, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 106.95M shares, increasing 0.01% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.16M shares of this stock.

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

34.333

Target Price

+50.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Catalyst Pharmaceuticals Inc is 9.23, ranking 8 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 152.61M, representing a year-over-year increase of 7.61%, while its net profit experienced a year-over-year increase of 5.79%.

Score

Industry at a Glance

Previous score

9.23

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.86

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Catalyst Pharmaceuticals Inc is 7.97, ranking 35 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 13.16, which is 178.92% below the recent high of 36.72 and 19.28% above the recent low of 10.62.

Score

Industry at a Glance

Previous score

7.97

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/157

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Catalyst Pharmaceuticals Inc is 9.25, ranking 3 out of 157 in the Pharmaceuticals industry. The average price target is 34.00, with a high of 40.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

9.25

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Catalyst Pharmaceuticals Inc is 7.03, ranking 30 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 24.95 and the support level at 21.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.20

Change

-0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of Catalyst Pharmaceuticals Inc is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 89.84%, representing a quarter-over-quarter decrease of 0.67%. The largest institutional shareholder is The Vanguard, holding a total of 8.41M shares, representing 6.88% of shares outstanding, with 0.89% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

15.95M

-2.09%

The Vanguard Group, Inc.

Star Investors

8.69M

-0.60%

State Street Investment Management (US)

6.41M

+16.92%

Deerfield Management Company, L.P.

4.97M

+72.77%

McEnany (Patrick James)

4.17M

-2.61%

Fundsmith LLP

3.36M

+24.17%

American Century Investment Management, Inc.

2.53M

+43.81%

Dimensional Fund Advisors, L.P.

2.46M

+28.87%

Geode Capital Management, L.L.C.

2.89M

+0.82%

Renaissance Technologies LLC

Star Investors

3.54M

+9.02%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Catalyst Pharmaceuticals Inc is 8.60, ranking 24 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Catalyst Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Catalyst Pharmaceuticals Inc

CPRX

8.32 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.83 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

8.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ligand Pharmaceuticals Inc

LGND

8.33 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.32 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment